Heather Bresch, CEO of Mylan, in an interview with IDA Ireland (Screenshot)
Drug company CEO Heather Bresch affectionately describes the humble EpiPen as her "baby," a once-middling product that she turned into a blockbuster. With aggressive advertising - and even more aggressive price hikes - Bresch has fostered the EpiPen into a bestseller that brings in more than $1 billion a year in revenue for Mylan Pharmaceuticals. But…
Report typos and corrections to corrections@rawstory.com.
For customer support contact support@rawstory.com.
